ClinicalTrials HQ

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting · NCT06072781 · Registry updated 2026-10-07
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerLow Grade Serous Ovarian CancerRecruitingPhase 32026-10-07NCT06072781

5 results · Page 1 of 1

106 results · Page 1 of 5

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Aalborg U.HAalborgDenmark1
AdventHealthOrlandoUnited States29
Agaplesion Markus KrankenhausFrankfurt am MainGermany6
Aichi Cancer Center HospitalAichiJapan1
Allegheny Health NetworkPittsburghUnited States13
AO CannizzaroCataniaItaly1
Asan Medical CenterSeoulSouth Korea338
Asplundh Cancer Pavilion | Jefferson HealthPhiladelphiaUnited States1
Atrium HealthCharlotteUnited States14
Auckland City HospitalAucklandNew Zealand68
Białostockie Centrum OnkologiiBialystokPoland2
British of ColumbiaVancouverCanada1
Cambridge University HospitalCambridgeUnited Kingdom2
Cancer Research South AustraliaAdelaideAustralia11
Centre Hospitalier de BesançonBesançonFrance1
Centre Hospitalier de l'Universite de Montreal (CHUM)MontrealCanada7
Centre Léon BérardLyonFrance77
Centre Oscar LambretLilleFrance73
Centro di Riferimento Oncologico (CRO)AvianoItaly2
Charité - Universitätsmedizin BerlinBerlinGermany25
Cleveland Clinic FoundationClevelandUnited States370
Clínico Virgen de La ArrixacaEl PalmarSpain1
European Institute of Oncology (IEO)MilanItaly1
Florida Cancer Specialists - SouthFort MyersUnited States12
Florida Cancer Specialists Research EastWest Palm BeachUnited States2